Tomohisa Akamatsu
Shinjuku, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Blood sLOX-1 Is Beneficial for Determining Severity of Neonatal Hypoxic-Ischemic Encephalopathy: A Nationwide Prospective Cohort Study.
Journal: Medical sciences (Basel, Switzerland)
Published: May 18, 2026
Relationship between insulin therapy for hyperglycemia and neurodevelopmental outcome in extremely preterm infants.
Journal: Early human development
Published: January 04, 2026
Rate of vertical transmission of coronavirus disease 2019 and effect of maternal vaccination: A prospective cohort study.
Journal: Pediatrics international : official journal of the Japan Pediatric Society
Published: June 18, 2024
LOX-1 mediates inflammatory activation of microglial cells through the p38-MAPK/NF-κB pathways under hypoxic-ischemic conditions.
Journal: Cell communication and signaling : CCS
Published: October 18, 2022
Adapting pediatric health care responses to the COVID-19 pandemic in Japan: A clinical perspective.
Journal: Global health & medicine
Published: May 17, 2022
Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1-Related Microglial Activation in Neonatal Hypoxic-Ischemic Encephalopathy: Morphologic Consideration.
Journal: The American journal of pathology
Published: December 16, 2020
A Pilot Study of Soluble Form of LOX-1 as a Novel Biomarker for Neonatal Hypoxic-Ischemic Encephalopathy.
Journal: The Journal of pediatrics
Published: February 15, 2018
LOX-1 is a novel therapeutic target in neonatal hypoxic-ischemic encephalopathy.
Journal: The American journal of pathology
Published: December 19, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026